CD123 binding agents and uses thereof
Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.
1. An isolated antibody, or an antigen-binding fragment thereof, that binds immunospecifically to Interleukin-3 Receptor alpha (IL3-Rα) SP2 and IL3-Rα SP1 comprising a heavy chain and a light chain having:
a. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 012, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 013, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 014, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 015, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 016, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 017; or
b. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 051, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 052, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 053, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 024, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 025, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 054.
2. The antibody or antigen-binding fragment of claim 1 , wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 120, and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:165.
3. The antibody or antigen-binding fragment of claim 1 , wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO: 136 and light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 168.
4. The antibody or antigen-binding fragment of any one of claims 1 to 3 , wherein said antibody or antigen-binding fragment is an IgG1 or IgG4 isotype.
5. An isolated cell expressing the antibody or bispecific antigen-binding fragment of any one of claims 1 to 3 .
6. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.
7. An isolated bispecific antibody or antigen-binding fragment comprising a first heavy chain (HC1), a second heavy chain (HC2), first light chain (LC1) and a second light chain (LC2), such that the HC1 and the LC1 pair to form a first antigen-binding site that immunospecifically binds IL3-Rα, and the HC2 and the LC2 pair to form a second antigen-binding site that immunospecifically binds CD3, or an IL3-Rα and CD3-bispecific binding fragment thereof, wherein:
i) HC1 and LC1 comprise either of the following pairs:
a. SEQ ID NO: 203 and SEQ ID NO: 204, or
b. SEQ ID NO: 205 and SEQ ID NO: 206, respectively; and
ii) HC2 and LC2 comprise any one of the following pairs:
a. SEQ ID NO: 193 and SEQ ID NO: 194,
b. SEQ ID NO: 195 and SEQ ID NO: 196,
c. SEQ ID NO: 197 and SEQ ID NO: 198,
d. SEQ ID NO: 199 and SEQ ID NO: 200, or
e. SEQ ID NO: 201 and SEQ ID NO: 202, respectively.
8. The bispecific antibody or antigen-binding fragment of claim 7 wherein HC1 comprises SEQ ID NO: 203 and LC1 comprises SEQ ID NO: 204 and HC2 comprises SEQ ID NO: 193 and LC2 comprises SEQ ID NO: 194.
9. An isolated cell expressing the bispecific antibody or antigen-binding fragment of claim 8 .
10. A pharmaceutical composition comprising the bispecific antibody or antigen-binding fragment of claim 8 and a pharmaceutically acceptable carrier.
11. The bispecific antibody or antigen-binding fragment of claim 7 wherein HC1 comprises SEQ ID NO: 205 and LC1 comprises SEQ ID NO: 206 and HC2 comprises SEQ ID NO: 193 and LC2 comprises SEQ ID NO: 194.
12. An isolated cell expressing the bispecific antibody or antigen-binding fragment of claim 11 .
13. A pharmaceutical composition comprising the bispecific antibody or antigen-binding fragment of claim 11 and a pharmaceutically acceptable carrier.
14. An isolated cell expressing the bispecific antibody or antigen-binding fragment of claim 7 .
15. A pharmaceutical composition comprising the bispecific antibody or antigen-binding fragment of claim 7 and a pharmaceutically acceptable carrier.
16. A bispecific antibody or antigen-binding fragment comprising:
a. a paired heavy and light chain that immunospecifically binds CD3, wherein said heavy chain comprises SEQ ID NO: 184 and said light chain comprises SEQ ID NO: 190, and
b. a paired heavy and light chain that immunospecifically binds IL3-Rα, wherein
i. said heavy chain comprises SEQ ID NO: 120 and said light chain comprises SEQ ID NO: 165, or
ii. said heavy chain comprises SEQ ID NO: 136 and said light chain comprises SEQ ID NO: 168.
17. An isolated cell expressing the bispecific antibody or antigen-binding fragment of claim 16 .
18. A pharmaceutical composition comprising the bispecific antibody or antigen-binding fragment of claim 16 and a pharmaceutically acceptable carrier.
19. A kit comprising the antibody or antigen-binding fragment of any one of claims 1 , 7 , 8 , 11 and 16 and packaging for the same.
20. The bispecific antibody or antigen-binding fragment of any one of claims 7 , 8 , 11 and 16 , wherein said bispecific antibody or antigen-binding fragment binds immunospecifically to IL3-Rα CD123 SP2 and IL3-Rα SP1.